160 related articles for article (PubMed ID: 23073666)
1. Effect of the fluoroquinolone antibacterial agent DX-619 on the apparent formation and renal clearances of 6β-hydroxycortisol, an endogenous probe for CYP3A4 inhibition, in healthy subjects.
Imamura Y; Murayama N; Okudaira N; Kurihara A; Inoue K; Yuasa H; Izumi T; Kusuhara H; Sugiyama Y
Pharm Res; 2013 Feb; 30(2):447-57. PubMed ID: 23073666
[TBL] [Abstract][Full Text] [Related]
2. 6β-Hydroxycortisol is an endogenous probe for evaluation of drug-drug interactions involving a multispecific renal organic anion transporter, OAT3/SLC22A8, in healthy subjects.
Imamura Y; Tsuruya Y; Damme K; Heer D; Kumagai Y; Maeda K; Murayama N; Okudaira N; Kurihara A; Izumi T; Sugiyama Y; Kusuhara H
Drug Metab Dispos; 2014 Apr; 42(4):685-94. PubMed ID: 24487120
[TBL] [Abstract][Full Text] [Related]
3. Associations of the CYP3A5*3 and CYP3A4*1G polymorphisms with the pharmacokinetics of oral midazolam and the urinary 6β-hydroxycortisol/cortisol ratio as markers of CYP3A activity in healthy male Chinese.
Chan SW; Xiao Y; Hu M; Yin OQ; Chu TT; Fok BS; Lee VH; Tomlinson B
J Clin Pharm Ther; 2016 Oct; 41(5):552-8. PubMed ID: 27511886
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of 6β-hydroxycortisol, 6β-hydroxycortisone, and a combination of the two as endogenous probes for inhibition of CYP3A4 in vivo.
Peng CC; Templeton I; Thummel KE; Davis C; Kunze KL; Isoherranen N
Clin Pharmacol Ther; 2011 Jun; 89(6):888-95. PubMed ID: 21490593
[TBL] [Abstract][Full Text] [Related]
5. Increase in urinary excretion of 6beta-hydroxycortisol in common marmosets as a marker of hepatic CYP3A induction.
Totsuka S; Watanabe T; Koyanagi F; Tanaka K; Yasuda M; Manabe S
Arch Toxicol; 1999; 73(4-5):203-7. PubMed ID: 10463384
[TBL] [Abstract][Full Text] [Related]
6. Separation and quantitative determination of 6α-hydroxycortisol and 6β-hydroxycortisol in human urine by high-performance liquid chromatography with ultraviolet absorption detection.
Shibasaki H; Okamoto S; Inoue R; Okita M; Yokokawa A; Furuta T
Anal Bioanal Chem; 2012 Mar; 402(9):2945-52. PubMed ID: 22318698
[TBL] [Abstract][Full Text] [Related]
7. Urinary 6beta-hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals.
Galteau MM; Shamsa F
Eur J Clin Pharmacol; 2003 Dec; 59(10):713-33. PubMed ID: 14605790
[TBL] [Abstract][Full Text] [Related]
8. The variability of liver graft function and urinary 6beta-hydroxycortisol to cortisol ratio during liver regeneration in liver transplant recipients.
Kishino S; Ogawa M; Takekuma Y; Sugawara M; Shimamura T; Furukawa H; Todo S; Miyazaki K
Clin Transplant; 2004 Apr; 18(2):124-9. PubMed ID: 15016124
[TBL] [Abstract][Full Text] [Related]
9. Dose-dependent inhibition of CYP3A activity by clarithromycin during Helicobacter pylori eradication therapy assessed by changes in plasma lansoprazole levels and partial cortisol clearance to 6beta-hydroxycortisol.
Ushiama H; Echizen H; Nachi S; Ohnishi A
Clin Pharmacol Ther; 2002 Jul; 72(1):33-43. PubMed ID: 12152002
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of CYP3A activity in humans using three different parameters based on endogenous cortisol metabolism.
Luo X; Li XM; Hu ZY; Cheng ZN
Acta Pharmacol Sin; 2009 Sep; 30(9):1323-9. PubMed ID: 19701237
[TBL] [Abstract][Full Text] [Related]
11. A background subtraction approach for determination of endogenous cortisol and 6β-hydroxycortisol in urine by UPLC-MS/MS with application in a within-day variability study in HIV-infected pregnant women.
Benzi JRL; Moreira FL; Marques MP; Duarte G; Suarez-Kurtz G; Lanchote VL
J Chromatogr B Analyt Technol Biomed Life Sci; 2020 May; 1144():122074. PubMed ID: 32247187
[TBL] [Abstract][Full Text] [Related]
12. The influence of taurine and L-carnitine on 6 β-hydroxycortisol/cortisol ratio in human urine of healthy volunteers.
Makhova AA; Shikh EV; Bulko TV; Sizova ZM; Shumyantseva VV
Drug Metab Pers Ther; 2019 Oct; 34(3):. PubMed ID: 31603853
[TBL] [Abstract][Full Text] [Related]
13. Prediction of fluoroquinolone-induced elevation in serum creatinine levels: a case of drug-endogenous substance interaction involving the inhibition of renal secretion.
Imamura Y; Murayama N; Okudaira N; Kurihara A; Okazaki O; Izumi T; Inoue K; Yuasa H; Kusuhara H; Sugiyama Y
Clin Pharmacol Ther; 2011 Jan; 89(1):81-8. PubMed ID: 21124314
[TBL] [Abstract][Full Text] [Related]
14. The Nonmetabolized β-Blocker Nadolol Is a Substrate of OCT1, OCT2, MATE1, MATE2-K, and P-Glycoprotein, but Not of OATP1B1 and OATP1B3.
Misaka S; Knop J; Singer K; Hoier E; Keiser M; Müller F; Glaeser H; König J; Fromm MF
Mol Pharm; 2016 Feb; 13(2):512-9. PubMed ID: 26702643
[TBL] [Abstract][Full Text] [Related]
15. Plasma 6β-hydroxycortisol to cortisol ratio as a less invasive cytochrome P450 3A phenotyping method.
Hirano R; Yokokawa A; Furihata T; Shibasaki H
Br J Clin Pharmacol; 2024 Apr; 90(4):1016-1026. PubMed ID: 38102865
[TBL] [Abstract][Full Text] [Related]
16. Renal uptake of substrates for organic anion transporters Oat1 and Oat3 and organic cation transporters Oct1 and Oct2 is altered in rats with adenine-induced chronic renal failure.
Komazawa H; Yamaguchi H; Hidaka K; Ogura J; Kobayashi M; Iseki K
J Pharm Sci; 2013 Mar; 102(3):1086-94. PubMed ID: 23280877
[TBL] [Abstract][Full Text] [Related]
17. Urinary 6beta-hydroxycortisol/17-hydroxycorticosteroids ratio as a measure of hepatic CYP3A4 capacity after enzyme induction.
Konishi H; Tanaka K; Minouchi T; Yamaji A
Ann Clin Biochem; 2004 Jul; 41(Pt 4):335-7. PubMed ID: 15298747
[TBL] [Abstract][Full Text] [Related]
18. Liquid chromatographic determination of urinary 6beta-hydroxycortisol to assess cytochrome p-450 3A activity in HIV positive pregnant women.
Homma M; Beckerman K; Hayashi S; Jayewardene AL; Oka K; Gambertoglio JG; Aweeka FT
J Pharm Biomed Anal; 2000 Sep; 23(4):629-35. PubMed ID: 10975239
[TBL] [Abstract][Full Text] [Related]
19. Investigation of Endogenous Compounds Applicable to Drug-Drug Interaction Studies Involving the Renal Organic Anion Transporters, OAT1 and OAT3, in Humans.
Tsuruya Y; Kato K; Sano Y; Imamura Y; Maeda K; Kumagai Y; Sugiyama Y; Kusuhara H
Drug Metab Dispos; 2016 Dec; 44(12):1925-1933. PubMed ID: 27638508
[TBL] [Abstract][Full Text] [Related]
20. Mirogabalin, a novel α
Yamamura N; Mikkaichi T; Itokawa KI; Hoshi M; Damme K; Geigner S; Baumhauer C
Xenobiotica; 2022; 52(9-11):997-1009. PubMed ID: 36170033
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
